Treace Medical Concepts, Inc. (TMCI)

Treace Medical Concepts' stock (TMCI) has experienced a significant decline over the past six months. Key events impacting the stock include revised revenue guidance in May 2024, which led to a plunge in the stock price. Treace Medical reported Q3 2025 revenue of $50.2 million, exceeding forecasts, but posted a net loss of $16.3 million, missing EPS expectations. The company announced the first surgical case using its Lapiplasty Lightning technology, designed to expand the Lapiplasty System. Analysts have trimmed their price targets for Treace Medical Concepts, citing recent guidance noise.

Demand seasonality for bunion correction procedures can be influenced by patient lifestyle and recovery considerations rather than a strict seasonal pattern. Summer can be an opportune time for bunion surgery due to the availability of downtime for recovery. Other perspectives suggest that fall or winter might be favorable for similar reasons. This indicates that while patients may have preferences for when to schedule surgery based on personal circumstances, there isn't a single, universally defined "peak season" for bunion correction procedures.

Treace Medical Concepts, Inc. (TMCI), based in Ponte Vedra Beach, Florida, specializes in foot and ankle surgical devices and biologics within the medical devices industry. Their primary product is the Lapiplasty® 3D Bunion Correction® System, which corrects bunion deformities by addressing the unstable joint. The company has expanded its product portfolio to offer a comprehensive suite of bunion and midfoot deformity solutions, including the Adductoplasty® Midfoot Correction System, the SpeedMTP™ Rapid Compression Implant, minimally invasive osteotomy systems like Nanoplasty™ and Percuplasty™, and SpeedPlate™ Rapid Compression Implants.

Treace Medical Concepts, Inc. is headquartered in Ponte Vedra Beach, Florida, U.S. The company's sales operations appear to be primarily focused within the United States, with job postings for sales representatives in various states. While the company acknowledges the need to comply with international laws and regulations, specific details regarding its current international operational or sales footprint are not explicitly provided.

Treace Medical Concepts maintains a commitment to ethical business practices and socially responsible industry conduct. The company endorses and abides by the AdvaMed Code and has received AdvaMed certification in support of its Compliance Program. It also adheres to the California Marketing Practices Act. There is no specific information available in the past year indicating events that have negatively or positively impacted Treace Medical Concepts' brand reputation beyond its financial performance and product developments.

Major institutional owners of Treace Medical Concepts, Inc. include CIBC Bancorp USA Inc., Armistice Capital, Llc, BlackRock, Inc., William Blair Investment Management, Llc, Vanguard Group Inc, Gagnon Securities Llc, Millennium Management Llc, CIBC Private Wealth Group, LLC, Jpmorgan Chase & Co, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. The largest individual shareholder is CEO John Treace, who holds a 21% stake in the company.